Mostrando 10 resultados de: 15
Filtros aplicados
Subtipo de publicación
Other(15)
Área temáticas
Enfermedades(7)
Farmacología y terapéutica(6)
Microorganismos, hongos y algas(6)
Medicina forense; incidencia de enfermedades(4)
Actuaciones públicas(1)
Área de conocimiento
Medicina veterinaria(8)
Inmunología(6)
Infección(5)
Microbiología(1)
Salud Pública(1)
Objetivos de Desarrollo Sostenible
ODS 17: Alianzas para lograr los objetivos(15)
ODS 3: Salud y bienestar(15)
ODS 10: Reducción de las desigualdades(10)
ODS 6: Agua limpia y saneamiento(3)
ODS 15: Vida de ecosistemas terrestres(2)
Origen
google(15)
A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (Sao Goncalo do Amaranto, RN)
OtherAbstract: Protection against canine kala-azar was investigated in naturally exposed dogs of an endemic area, vPalabras claves:Autores:Gulnara Borja-CabreraFuentes:googleEffective immunotherapy against canine visceral leishmaniasis with the FML-vaccine
OtherAbstract: The potential effect of the fucose mannose ligand (FML)-vaccine on immunotherapy of canine visceralPalabras claves:Autores:Gulnara Borja-CabreraFuentes:googleHuman Visceral Leishmaniasis: Ethical and Legal Reflections on the Canine Reservoir Control in Brazil
OtherAbstract: Brazil currently faces difficulties in combating human visceral leishmaniasis. According to the WorlPalabras claves:Autores:Gulnara Borja-CabreraFuentes:googleFML vaccine against canine visceral leishmaniasis: from second-generation to synthetic vaccine
OtherAbstract: The Leishmania donovani glycoprotein fraction, known as FML, successfully underwent preclinical andPalabras claves:Autores:Gulnara Borja-CabreraFuentes:googleIgG1/IgG2 antibody dichotomy in sera of vaccinated or naturally infected dogs with visceral leishmaniosis.
OtherAbstract: Canine antibody I-G. IgG1 and IgG2 anti-FML responses were investigated in dogs vaccinated with thePalabras claves:Autores:Gulnara Borja-CabreraFuentes:googleImmunogenicity assay of the Leishmune® vaccine against canine visceral leishmaniasis in Brazil
OtherAbstract: Leishmune® is the industrialized version of the FML-saponin vaccine which has been shown to developPalabras claves:Autores:Gulnara Borja-CabreraFuentes:googleImmunotherapy with the saponin enriched-Leishmune® vaccine versus immunochemotherapy in dogs with natural canine visceral leishmaniasis
OtherAbstract: Leishmune®, the first licensed vaccine for prophylaxis against canine visceral leishmaniasis (CVL) aPalabras claves:Autores:Gulnara Borja-CabreraFuentes:googleTHE FML-ELISA ASSAY IN DIAGNOSIS OF CANINE VISCERAL LEISHMANIASIS OF A RECENT OUTBREAK AT ARACATUBA, SAO PAULO
OtherAbstract:Palabras claves:Autores:Gulnara Borja-CabreraFuentes:googleThe FML-vaccine (Leishmune®) against canine visceral leishmaniasis: a transmission blocking vaccine
OtherAbstract: Transmission blocking vaccines are one of the control strategies for vector-transmitted protozoan diPalabras claves:Autores:Gulnara Borja-CabreraFuentes:googleThe Leishmune® s nucleoside hydrolase DNA vaccine as an aid in immunotherapy of canine visceral leishmaniasis
OtherAbstract: The Nucleoside hydrolase of Leishmania donovani (NH36) is the main antigen of Leishmune®, the firstPalabras claves:Autores:Gulnara Borja-CabreraFuentes:google